Skip to main content
Home
Home

FDA Human Foods Program Details 2025 Guidance Agenda: Key Topics and Priorities

FDA Human Foods Program Details 2025 Guidance Agenda: Key Topics and Priorities

Grocery shopping cart in a food aisle

Key Takeaways:

On June 30, 2025, the U.S. Food and Drug Administration (FDA) published its proposed Human Foods Program (HFP) guidance agenda for 2025. The agenda identifies new topics under consideration for future guidance and potential revisions to existing guidance documents. Of particular note, the agenda includes forthcoming draft guidance documents addressing action levels for cadmium and inorganic arsenic in food intended for babies and young children. 

The complete list of potential new guidance topics includes:

  • New Dietary Ingredient (NDI) Notifications and Related Issues: Identity and Safety Information About the NDI: Guidance for Industry
  • Food Colors Derived from Natural Sources: Fruit Juice and Vegetable Juice as Color Additives in Food; Draft Guidance for Industry
  • Action Levels for Cadmium in Food Intended for Babies and Young Children; Draft Guidance for Industry       
  • Action Levels for Inorganic Arsenic in Food Intended for Babies and Young Children; Draft Guidance for Industry
  • Action Level for Opiate Alkaloids on Poppy Seeds: Draft Guidance for Industry
  • Hazard Analysis and Risk-Based Preventive Controls for Human Food; Chapter 12: Preventive Controls for Chemical Hazards
  • The Food Traceability Rule: Questions and Answers; Draft Guidance for Industry

The HFP was established in 2023 as part of the FDA’s reorganization to streamline oversight and strengthen public health protections. The program consolidated the Office of Food Policy and Response with field operations from the Office of Regulatory Affairs. 

As detailed in the notice, the HFP plans to develop a draft or final guidance on each of the listed topics by the end of December 2025. However, the HFP is not bound by this list of topics or required to issue all proposed guidance documents.

FDA guidance documents reflect the agency’s current thinking on specific topics and are intended to provide information to help stakeholders anticipate and prepare for potential regulatory changes.

If you have any questions about the proposed guidance topics or how they may affect your operations, please contact members of Perkins Coie’s food regulatory team.

Summer Associate Annalise Hinkle contributed to this article.

Print and share

Authors

Profile Picture
Counsel
TTobin@perkinscoie.com

Notice

Before proceeding, please note: If you are not a current client of Perkins Coie, please do not include any information in this e-mail that you or someone else considers to be of a confidential or secret nature. Perkins Coie has no duty to keep confidential any of the information you provide. Neither the transmission nor receipt of your information is considered a request for legal advice, securing or retaining a lawyer. An attorney-client relationship with Perkins Coie or any lawyer at Perkins Coie is not established until and unless Perkins Coie agrees to such a relationship as memorialized in a separate writing.

206.359.3157
Profile Picture
Associate
EMolineux@perkinscoie.com

Notice

Before proceeding, please note: If you are not a current client of Perkins Coie, please do not include any information in this e-mail that you or someone else considers to be of a confidential or secret nature. Perkins Coie has no duty to keep confidential any of the information you provide. Neither the transmission nor receipt of your information is considered a request for legal advice, securing or retaining a lawyer. An attorney-client relationship with Perkins Coie or any lawyer at Perkins Coie is not established until and unless Perkins Coie agrees to such a relationship as memorialized in a separate writing.

206.359.6014

Explore more in

Related insights

Home
Jump back to top